Navigation Links
Endo Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:4/29/2009

CHADDS FORD, Pa., April 29 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today reported financial results for the first quarter of 2009, including results beginning on February 23, 2009 for Indevus Pharmaceuticals, which Endo acquired during the quarter.

Net sales during the first quarter of 2009 increased 16% to $335.3 million compared with $290.3 million in the first quarter of 2008. Net income for the three months ended March 31, 2009 was $39.0 million compared with $59.5 million in the comparable 2008 period. As detailed in the Supplemental Financial Information below, adjusted net income for the three months ended March 31, 2009 was $79.0 million compared with $68.2 million in the same period in 2008.

Diluted earnings per share for the three months ended March 31, 2009 were $0.33 compared with $0.44 in the first quarter of 2008. Adjusted diluted earnings per share for the three months ended March 31, 2009 were $0.67 compared with $0.51 in the same period in 2008.

"We had a solid first quarter during which we diversified our commercial business beyond pain management, reorganized our sales and marketing and R&D groups, and repositioned our company for sustainable future growth," said Dave Holveck, president and chief executive officer of Endo Pharmaceuticals. "I believe our broader therapeutic focus on urology and oncology and more capable specialty infrastructure will enable us to meet aggressive long-term growth targets and adapt quickly to a changing healthcare environment."

Selected Product Review

PAIN PRODUCTS

LIDODERM(R): For the quarter ended March 31, 2009, net sales of LIDODERM decreased 5% to $171.6 million compared with $180.5 million in the same period a year ago. Prescription volume for LIDODERM decrease
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... August 21, 2014 Living in a ... atmosphere that comes along with it. A quality Home ... that such amenities are available. , ... Fayetteville, Georgia and Community Association Management, LLC made a ... Parks Company to provide an additional amenity for their ...
(Date:8/21/2014)... the coronary arteries of chronic kidney disease patients may ... to a new study in the Journal of ... Researchers at the Johns Hopkins Bloomberg School of Public ... used measures of subclinical atherosclerosis in predicting the risk ... Approximately 50 percent of all patients with chronic kidney ...
(Date:8/21/2014)... 2014 Improv performers from Fun House ... dementia at Silverado Turtle Creek memory care community in ... entertainers ranging from ages 10 to 16, delivers a ... 40-minute set. The troupe's philosophy is that improv is ... them to touch audiences regardless of their circumstance — ...
(Date:8/21/2014)... 2014 The City of Garden Grove ... and programming for its inaugural “Re:Imagine Garden Grove – ... 2014, from 11 a.m. to 4 p.m., 2.85-miles of ... and the downtown will be filled with diverse music, ... Arts Resources (CARS), for all to enjoy. , The ...
(Date:8/21/2014)... seniors, dimming vision may be tied to poorer survival, new ... aged 65 to 84, who were assessed when they enrolled ... later. Vision loss over time was associated with an ... period, the researchers reported. Although the study couldn,t prove ... University in West Lafayette, Ind., offered up some theories on ...
Breaking Medicine News(10 mins):Health News:Recreation is the Heart of the Community at Simpson Mill Plantation; Chooses American Parks Company™ for New Playground Equipment 2Health News:Recreation is the Heart of the Community at Simpson Mill Plantation; Chooses American Parks Company™ for New Playground Equipment 3Health News:Measuring calcium buildup to predict heart disease in those with chronic kidney disease 2Health News:Unicorn Clearance Improv Troupe Brings Laughter to Residents with Dementia at Silverado Memory Care 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 3Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 4Health News:Failing Vision Tied to Shorter Lifespans for Seniors 2
... medical practice of Acupuncture along with commonly used ... side effects of chemotherapy for breast cancer patients, ... are to be believed. , , ,According to ... electro-acupuncture was more effective in controlling vomiting than ...
... In what can be a watershed in cancer research, ... have used nuclear transfer technology to harvest life saving ... The same team had earlier cornered world wide fame ... Dolly – the world’s first cloned mammal: Using the ...
... In India Kidney Stones are not uncommon problem due to the ... up of Calcium, Oxalate and phosphates. The cause of stone disease ... water is a risk factor for stone disease. , ... is a tiny bacteria called Nano bacteria., ,These bacteria ...
... be responsible for a form of the herpes virus that ... sarcoma causes purple skin blotches and can also attack the ... normal disease defenses but attacks those with weakened immune system ... virus 8 was discovered six years ago. Almost 30% to ...
... cancer can effect men over the age of 40 years ... cancer. Usually it goes undetected till it is advanced and ... about this condition and now men over the age of ... ,One of the most promising "tumour markers" in medicine ...
... hormone replacement prescription drug, levothyroxine sodium (Unithroid) for hypothyroidism in ... the United States by the FDA. , ,The ... range of metabolic processes within the body in all age ... growth and intellectual development. , ,Low levels of thyroid ...
Cached Medicine News:
(Date:8/21/2014)...  Zacks.com announces the list of stocks featured in the ... the latest news and events impacting stocks and the financial ... HPQ - Free Report ), IBM (NYSE: IBM ... - Free Report ), GlaxoSmithKline plc (NYSE: GSK - ... - Free Report ). Today, Zacks is promoting ...
(Date:8/21/2014)...  ACI Clinical ( www.aciclinical.com ) announces a ... Using this solution, trial sponsors can ... costs and receive the same expertise that has ... Leveraging a decade of DMC experience ... statistical programming and meeting facilitation), ACI analyzed DMC ...
(Date:8/21/2014)... , Aug. 21, 2014 InfinityQS International, ... Manufacturing Intelligence , today announces Infusion Chicago, ... event will be held Oct. 9-10, 2014, at ... designed to showcase the necessity for implementing a ... and Manufacturing Intelligence to gain insight into production ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 2The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 4The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 5The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 6The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 7The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 8The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 9The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 10The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 11ACI Clinical: Innovation and Savings in Data Safety Monitoring Committees 2InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2
... SYDNEY, May 23, 2012 HeartWare International, Inc. (NASDAQ: ... of less invasive, miniaturized circulatory support technologies revolutionizing the ... has received an expanded European label for long-term use ... at risk of death from refractory, end-stage heart failure. ...
... ATLANTA, May 23, 2012   CryoLife, Inc. (NYSE: ... focused on cardiac and vascular surgery, announced today that ... Company, LLC One-on-One Investor Conference on Thursday, May 31, ... vice president, chief operating officer, and chief financial officer ...
Cached Medicine Technology:HeartWare International Receives CE Mark Addendum, Expanding Label to Include All Patients at Risk of Death From Refractory, End-Stage Heart Failure 2HeartWare International Receives CE Mark Addendum, Expanding Label to Include All Patients at Risk of Death From Refractory, End-Stage Heart Failure 3CryoLife to Participate in 3rd Annual Benchmark Company, LLC One-on-One Investor Conference 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: